Taparia Tools Limited (BOM:505685)
India · Delayed Price · Currency is INR 28.04
+1.33 (4.98%)
At close: Jul 24, 2025
Intra-Cellular Therapies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 9,129 | 8,285 | 7,645 | 6,676 | 5,361 | Upgrade |
| 9,129 | 8,285 | 7,645 | 6,676 | 5,361 | Upgrade | |
Revenue Growth (YoY) | 10.18% | 8.38% | 14.51% | 24.54% | 13.69% | Upgrade |
Cost of Revenue | 4,799 | 4,877 | 4,798 | 4,106 | 3,374 | Upgrade |
Gross Profit | 4,330 | 3,408 | 2,847 | 2,571 | 1,986 | Upgrade |
Selling, General & Admin | 428.19 | 407.57 | 377.23 | 320.85 | 292.62 | Upgrade |
Other Operating Expenses | 2,334 | 1,736 | 1,528 | 1,375 | 1,047 | Upgrade |
Operating Expenses | 2,798 | 2,161 | 1,922 | 1,714 | 1,357 | Upgrade |
Operating Income | 1,532 | 1,247 | 925.41 | 856.69 | 629.43 | Upgrade |
Interest Expense | -0.19 | -1.61 | -0.97 | -0.01 | -0.61 | Upgrade |
Interest & Investment Income | 1.37 | 0.84 | 5.77 | 0.22 | 1.4 | Upgrade |
Currency Exchange Gain (Loss) | 0.53 | 0.28 | 0.54 | -0.11 | 0.03 | Upgrade |
Other Non Operating Income (Expenses) | 9.98 | 7.43 | 9.69 | 3.38 | 2.41 | Upgrade |
EBT Excluding Unusual Items | 1,543 | 1,254 | 940.44 | 860.17 | 632.65 | Upgrade |
Gain (Loss) on Sale of Investments | 105.75 | 80.93 | 26.96 | 13.75 | 11.38 | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.57 | 0.07 | 0.44 | 0.36 | Upgrade |
Asset Writedown | -0.43 | -0.84 | -0.22 | -0.48 | - | Upgrade |
Pretax Income | 1,649 | 1,334 | 967.24 | 873.88 | 644.4 | Upgrade |
Income Tax Expense | 423.57 | 336.62 | 244.04 | 222.98 | 161.04 | Upgrade |
Net Income | 1,225 | 997.66 | 723.2 | 650.9 | 483.36 | Upgrade |
Net Income to Common | 1,225 | 997.66 | 723.2 | 650.9 | 483.36 | Upgrade |
Net Income Growth | 22.81% | 37.95% | 11.11% | 34.66% | 58.02% | Upgrade |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | Upgrade |
EPS (Basic) | 80.72 | 65.73 | 47.65 | 42.88 | 31.84 | Upgrade |
EPS (Diluted) | 80.72 | 65.73 | 47.65 | 42.88 | 31.84 | Upgrade |
EPS Growth | 22.81% | 37.95% | 11.11% | 34.66% | 58.02% | Upgrade |
Free Cash Flow | 721.33 | 1,154 | 829.39 | 317.03 | 186.14 | Upgrade |
Free Cash Flow Per Share | 47.52 | 76.05 | 54.64 | 20.89 | 12.26 | Upgrade |
Dividend Per Share | 50.000 | 40.000 | 31.000 | 34.500 | - | Upgrade |
Dividend Growth | 25.00% | 29.03% | -10.14% | - | - | Upgrade |
Gross Margin | 47.43% | 41.13% | 37.24% | 38.51% | 37.05% | Upgrade |
Operating Margin | 16.78% | 15.05% | 12.11% | 12.83% | 11.74% | Upgrade |
Profit Margin | 13.42% | 12.04% | 9.46% | 9.75% | 9.02% | Upgrade |
Free Cash Flow Margin | 7.90% | 13.93% | 10.85% | 4.75% | 3.47% | Upgrade |
EBITDA | 1,547 | 1,258 | 938.28 | 868.22 | 638.31 | Upgrade |
EBITDA Margin | 16.94% | 15.18% | 12.27% | 13.00% | 11.91% | Upgrade |
D&A For EBITDA | 14.96 | 11.34 | 12.87 | 11.53 | 8.87 | Upgrade |
EBIT | 1,532 | 1,247 | 925.41 | 856.69 | 629.43 | Upgrade |
EBIT Margin | 16.78% | 15.05% | 12.11% | 12.83% | 11.74% | Upgrade |
Effective Tax Rate | 25.69% | 25.23% | 25.23% | 25.52% | 24.99% | Upgrade |
Revenue as Reported | 9,249 | 8,377 | 7,689 | 6,695 | 5,378 | Upgrade |
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.